P160048/S031: Eversense Continuous Glucose Monitoring System
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS) protocol.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Senseonics, Incorporated. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 19, 2026 to Mar 19, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QCD appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P160048, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 20451 Seneca Meadows Pkwy., Germantown, MD, 20876. Recorded on P160048/S031, decision dated Mar 19, 2026.
Continuous glucose monitor, implanted, adjunctive use.
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS) protocol.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.